logo
Origins of COVID-19 still unclear according to final report from WHO expert group

Origins of COVID-19 still unclear according to final report from WHO expert group

CBC27-06-2025
An expert group charged by the World Health Organization to investigate how the COVID-19 pandemic started released its final report on Friday, reaching an unsatisfying conclusion: Scientists still aren't sure how the worst health emergency in a century began.
At a news briefing, Marietjie Venter, the group's chair, said that most scientific data supports the hypothesis that the new coronavirus jumped to humans from animals.
That was also the conclusion drawn by the first WHO expert group that investigated the pandemic's origins in 2021, when scientists concluded the virus likely spread from bats to humans, via another intermediary animal. At the time, WHO said a lab leak was "extremely unlikely."
Venter said that after more than three years of work, WHO's expert group was unable to get the necessary data to evaluate whether or not COVID-19 was the result of a lab accident, despite repeated requests for hundreds of genetic sequences and more detailed biosecurity information that were made to the Chinese government.
"Therefore, this hypothesis could not be investigated or excluded," she said. "It was deemed to be very speculative, based on political opinions and not backed up by science."
She said that the 27-member group did not reach a consensus; one member resigned earlier this week and three others asked for their names to be removed from the report.
Venter said there was no evidence to prove that COVID-19 had been manipulated in a lab, nor was there any indication that the virus had been spreading before December 2019 anywhere outside of China.
"Until more scientific data becomes available, the origins of how SARS-CoV-2 entered human populations will remain inconclusive," Venter said, referring to the scientific name for the COVID-19 virus.
WHO Director General Tedros Adhanom Ghebreyesus said it was a "moral imperative" to determine how COVID began, noting that the virus killed at least 20 million people, wiped at least $10 trillion US from the global economy and upended the lives of billions.
Last year, The Associated Press found that the Chinese government froze meaningful domestic and international efforts to trace the virus's origins in the first weeks of the outbreak in 2020 and that WHO itself may have missed early opportunities to investigate how COVID-19 began.
U.S. President Donald Trump has long blamed the emergence of the coronavirus on a laboratory accident in China, while a U.S. intelligence analysis found there was insufficient evidence to prove the theory.
Chinese officials have repeatedly dismissed the idea that the pandemic could have started in a lab, saying that the search for its origins should be conducted in other countries.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SciMaster Leads the Scientific Agent Revolution in the AI Scientist Era
SciMaster Leads the Scientific Agent Revolution in the AI Scientist Era

Globe and Mail

time5 hours ago

  • Globe and Mail

SciMaster Leads the Scientific Agent Revolution in the AI Scientist Era

Shanghai JiaoTong University, DP Technology, and the Institute for Advanced Algorithms Research (Shanghai) jointly introduces SciMaster, the World's First "Universal Research Intelligence Agent", committed to providing researchers worldwide with an accessible, master-level expert assistant—it overcommes the barriers regarding the escalating tool complexity traps in multidiscplicnary collaboration, and establishes a transparent, controllable intelligence ecosystem anchored in read-compute-execute integration. SciMaster transforms the vision of AI for Science into a tangible reality for researchers worldwide. Shanghai JiaoTong University, DP Technology, and the Institute for Advanced Algorithms Research (Shanghai) jointly launches SciMaster, built upon Innovator, which is a genuinely general-purpose scientific foundation model. SciMaster demonstrates master-tier expertise in generating comprehensive research reports. When addressing scientific queries, it deconstructs queries into subtasks, dynamically deploys three retrieval modes (WebSearch, WebParse, PaperSearch) across global resources, and synthesizes domain-specific data, patents, and literature into actionable research dossiers. SciMaster introduces chain-of-thought editing, enabling researchers to intervene in its logic. During task planning, users can pause execution, modify parameters in real-time, and co-optimize outcomes—acting as "commanders" in collaborative reasoning. SciMaster leverages Uni-Lab's MCP service to connect instruments, software, and workflows—establishing a closed-loop computational-experimental ecosystem spanning hardware, software, personnel, and data. SciMaster embraces open science by enabling researchers to upgrade scientific tools into agents with one click. Integration with DeepModeling features open contribution-evaluation mechanisms quantifying human-AI value, 1,000+ Agent-ready tools and hundreds of applications (e.g., ChemMaster for molecular-scale design, and global access to Lingang Laboratory's "YuanSheng" modules (literature/patent analysis, omics mining). "We are incredibly excited about the launch of SciMaster," said the SciMaster Team. "It reshapes the physical world through industrial revolutions and the information realm via computing. SciMaster embodies the "revolutionary instrument" propelling humanity beyond cognitive frontiers For more information about SciMaster, visit: About SciMaster SciMaster is a general-purpose scientific AI agent, aimed at transforming the vision of AI for Science into a tangible reality for researchers worldwide. SciMaster's commitment to advancing scientific research is further demonstrated by its active participation in esteemed conferences such as WAIC 2025. Media Contact Company Name: SciMaster Contact Person: The SciMaster Team Email: Send Email Country: China Website:

Kim Jong Un slams South Korea-U.S. drills during an inspection of his most powerful warship
Kim Jong Un slams South Korea-U.S. drills during an inspection of his most powerful warship

CTV News

time6 hours ago

  • CTV News

Kim Jong Un slams South Korea-U.S. drills during an inspection of his most powerful warship

In this photo provided by the North Korean government, North Korean leader Kim Jong Un, center, the warship Choe Hyon in Nampo, North Korea, on Aug. 18, 2025. Independent journalists were not given access to cover the event depicted in this image distributed by the North Korean government. The content of this image is as provided and cannot be independently verified. Korean language watermark on image as provided by source reads: "KCNA" which is the abbreviation for Korean Central News Agency. (Korean Central News Agency/Korea News Service via AP)

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Globe and Mail

time11 hours ago

  • Globe and Mail

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunities for the NMPA to prioritize the allocation of review resources to expedite the regulatory review and approval process. 'We are excited that TTFields has been granted the Innovative Medical Device Designation, a status that offers expedited registration and priority review by the NMPA. This designation also allows us to submit the application in China before approval in the country of origin,' said Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. 'Pancreatic cancer remains one of the most challenging cancers to treat globally, with approximately 134,000 new cases diagnosed annually in China alone. We are on track to submit for regulatory approval in China in the second half of 2025 and look forward to collaborating closely with the NMPA throughout the review process.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields. Zai Lab participated in the study in Greater China (mainland China, Hong Kong, Macau and Taiwan, collectively). In August 2019, the NMPA granted Innovative Medical Device Designation for Optune ® in China for the treatment of newly diagnosed and recurrent glioblastoma (GBM). Zai Lab subsequently submitted the regulatory application in September 2019 and received approval in May 2020. Optune is a registered trademark of Novocure GmbH, and Zai Lab markets Optune under license from Novocure GmbH. About PANOVA-3 PANOVA-3 is an international prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of TTFields therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About Pancreatic Cancer in China Pancreatic cancer is one of the most common and deadliest cancers globally. In China, there were an estimated 134,374 new cases and 131,203 cancer deaths in 2022, and it is the sixth leading cause of cancer mortality in China 1. Pancreatic cancer has a 5-year survival rate of less than 10%, making it the malignancy with the lowest survival rate in China 2. The patients with locally advanced, unresectable pancreatic cancer are no longer operable, so chemotherapy with or without radiation is the only treatment option, with a median overall survival only nine to twelve months. 1 Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590. 2 Hu JX, Zhao CF, Chen WB et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27: 4298-4321. About Tumor Treating Fields Tumor Treating Fields (TTFields) is a cancer therapy that uses electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multi mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibitors, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effects on cancer cells, visit About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for developing and commercializing TTFields therapy, the potential benefits of TTFields therapy, and the potential treatment of pancreatic cancer. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store